ABP1618

(I) Objectives of Phase I Study 1. Primary Objectives To evaluate the safety and tolerability of ABP1618 tablets in patients with advanced solid tumors; to determine the recommended dose (RP2D) and dosing regimen for subsequent clinical trials. 2. Secondary Objectives To study the pharmacokinetic (PK) characteristics of single and multiple doses of ABP1618 tablets in patients with advanced solid tumors; To preliminarily evaluate the cardiac safety of ABP1618 tablets, including the possibility of correcting QT interval (QTc) prolongation, and to evaluate the PK/QTc relationship; To preliminarily evaluate the effectiveness of ABP1618 tablets in the treatment of advanced solid tumors. (II) Objectives of Phase II Study 1. Primary Objectives To preliminarily evaluate the effectiveness of ABP1618 tablets in target patients with advanced solid tumors. 2. Secondary Objectives To evaluate the safety of ABP1618 tablets in target patients with advanced solid tumors.